Abstract: A pressed powder material according to embodiments is a pressed powder material including first magnetic metal particles having a first magnetic metal phase containing Fe and Co; and second magnetic metal particles having a second magnetic metal phase containing Fe, in which when the amounts of Co with respect to the total amounts of Fe and Co of the first and second magnetic metal particles are designated as Co1 and Co2, respectively, the ratio of Co2 to Co1 (Co2/Co1) is from 0 to 0.5, the average value of the ratio of the major axis to the minor axis is 2 or greater for the first magnetic metal particles and 1 or greater for the second magnetic metal particles, the second magnetic metal particles are present between the particles of the first magnetic metal particles, and the average value of the major axis of the second magnetic metal particles is equal to or longer than the average value of the major axis of the first magnetic metal particles.

Abstract: The present invention relates to novel fragments of apolipoprotein E (ApoE). These ApoE fragments have a variety of uses including as components of vaccine compositions, particularly vaccines for the prevention or treatment of neurological disorders such as Alzheimer's disease. The ApoE fragments may also be used in screening methods and methods of detection.

Abstract: Disclosed is a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, which is effective as a therapeutic or prophylactic agent for a disease induced by A?, wherein Ar1 represents an imidazolyl group which may be substituted with a C1-6 alkyl group, or the like; Ar2 represents a phenyl group which may be substituted with a C1-6 alkoxy group, or the like; X1 represents a double bond, or the like; and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, or the like.

Abstract: An input protection circuit includes: a first transistor of a field-effect type coupled in series between an input terminal and an electronic circuit, the input terminal receiving an input voltage, the electronic circuit receiving an input voltage, the first transistor switching to an off-state in a case where the input voltage is higher than a positive power supply voltage of the electronic circuit; a second transistor of a field-effect type coupled in series between the first transistor and the electronic circuit, the second transistor switching to an off-state in a case where the input voltage is lower than the negative power supply voltage of the electronic circuit; and a voltage control circuit configured to maintain gate-source voltages of the first transistor and the second transistor as voltages within a power supply voltage range of the electronic circuit based on the input voltage.

Abstract: A copolymerized polyether polyamide resin for coating on or for impregnation to a woven or knitted fabric, wherein elongation and elastic modulus of the copolymerized polyether polyamide resin are not less than 1000% and not more than 15 MPa, respectively. The copolymerized polyether polyamide resin has a constitution wherein said copolymerized polyether polyamide resin is such that a soft segment comprising a polyether polyamide constituted from a polyether diamine compound and a dicarboxylic acid compound is bonded to a hard segment comprising a polyamide constituted from an aminocarboxylic acid compound and/or a lactam compound.

Abstract: An input protection circuit includes: a first transistor of a field-effect type coupled in series between an input terminal and an electronic circuit, the input terminal receiving an input voltage, the electronic circuit receiving an input voltage, the first transistor switching to an off-state in a case where the input voltage is higher than a positive power supply voltage of the electronic circuit; a second transistor of a field-effect type coupled in series between the first transistor and the electronic circuit, the second transistor switching to an off-state in a case where the input voltage is lower than the negative power supply voltage of the electronic circuit; and a voltage control circuit configured to maintain gate-source voltages of the first transistor and the second transistor as voltages within a power supply voltage range of the electronic circuit based on the input voltage.

Abstract: The present invention relates to a novel two cyclic cinnamide compound and a pharmaceutical agent comprising the compound as an active ingredient. The two cyclic cinnamide compound represented by the general formula (I): wherein represents a single bond or a double bond; Ar1 represents a phenyl group or pyridinyl group that may be substituted with 1 to 3 substituents; R1 and R2 each represent a C1-6 alkyl group, a hydroxyl group, or the like; Z1 represents a methylene group or vinylene group, which may be substituted with 1 or 2 substituents selected from Substituent Group A1, an oxygen atom, or an imino group that may be substituted with a substituent selected from Substituent Group A1; and p, q, and r each represent an integer of 0 to 2, which has an effect of reducing A?40 and A?42 production, and thus is particularly useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? such as Alzheimer's disease or Down's syndrome.

Abstract: The present invention relates to a compound represented by formula (I): wherein R1 represents a C1-3 alkyl group, R2 represents a hydrogen atom or a C1-3 alkyl group, Ar represents a phenyl group or the like which may be substituted with 1 to 3 substituents, X represents an oxygen atom or the like, n and m are the same or different and integers of 0 to 2, or a pharmacologically acceptable salt, and use thereof as a medicament.

Abstract: A fabric for an airbag includes a synthetic fiber woven fabric in which at least one side thereof is coated with a synthetic resin. A range of 0.1 to 10 g/m2 of the synthetic resin is adhered to the synthetic fiber woven fabric having a cover factor of less than 2000 and a FR value of 55% or more. Air permeability of the fabric under a pressure difference of 100 kPa after adhesion is 0.01 to 1.00 L/cm2/min. The synthetic resin can be a polyamide-based resin having a soft segment comprising a polyol with a number average molecular weight of 100 to 5000.

Abstract: A woven fabric for an airbag includes a synthetic fiber woven fabric having a cover factor of 2000 to 2500 in which at least one side thereof is coated with a synthetic resin. Air permeability of the woven fabric under a pressure difference of 100 kPa is 0.01 to 1.00 L/cm2/min. A resin film is present at an upper part of a single yarn at a thickness of 2 ?m or less on a central cross section of a weaving yarn part. A resin film is present at an upper part of a single yarn at a thickness of 2 to 30 ?m on a cross section at a border between weaving yarn parts. The synthetic resin can be a polyamide-based resin that includes a polyether compound of a number average molecular weight of 100 to 5000 as a soft segment.

Abstract: The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by A?.

Abstract: The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by A?.

Abstract: A compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Ar2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, X1 represents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by A?.

Abstract: An object of the present invention is to provide a woven fabric for an airbag which is of low cost, is excellent in accommodability, and has air permeability satisfying the human body initial constraining performance. The present invention provides a woven fabric for an airbag comprising a synthetic fiber woven fabric having a cover factor represented by the equation 1 of 2000 to 2500 in which at least one side thereof is coated with a synthetic resin, wherein air permeability of the woven fabric under a pressure difference of 100 kPa is 0.01 to 1.00 L/cm2/min, and a resin film is present at an upper part of a single yarn at a thickness of 2 ?m or less on a central cross section of a weaving yarn part, while a resin film is present at an upper part of a single yarn at a thickness of 2 to 30 ?m on a cross section at a border between weaving yarn parts.

Abstract: An object of the present invention is to provide a fabric for an airbag which is of low cost, is excellent in accommodability, and has air permeability satisfying the human body initial constraining performance. The present invention provides a fabric for an airbag comprising a synthetic fiber woven fabric in which at least one side thereof is coated with a synthetic resin, characterized in that a range of 0.1 to 10 g/m2 of a synthetic resin is adhered to the synthetic fiber woven fabric having a cover factor represented by the equation 1 of less than 2000 and FR represented by the equation 2 of 55% or more, and air permeability of the fabric under a pressure difference of 100 kPa after adhesion is 0.01 to 1.00 L/cm2/min.

Abstract: A compound represented by Formula (I) is provided: wherein Ar1 represents an imidazolyl group which may be substituted with 1 to 3 substituents; Ar2 represents a phenyl group which may be substituted with 1 to 3 substituents; X1 represents (1) —C?C— or (2) a double bond etc., which may be substituted; R1 and R2 represent, for example, a C1-6 alkyl group which may be substituted, or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents.

Abstract: A compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Ar2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, X1 represents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by A?.

Abstract: The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by A?.